$0.69
-0.0074[-1.06%]
Last update: 9:17AM Get Real Time Here
Atara Biotherapeutics
(NASDAQ:ATRA)Atara Biotherapeutics Stock (NASDAQ:ATRA), Analyst Ratings, Price Targets, Predictions
Atara Biotherapeutics Inc has a consensus price target of $9.77, established from looking at the 26 latest analyst ratings. The last 3 analyst ratings were released from Stifel, Goldman Sachs, and Evercore ISI Group on April 1, 2024, November 10, 2023, and November 9, 2023. With an average price target of $0.93 between Stifel, Goldman Sachs, and Evercore ISI Group, there's an implied 35.27% upside for Atara Biotherapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
Goldman Sachs
Evercore ISI Group
HC Wainwright & Co.
Mizuho
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Atara Biotherapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/01/2024 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 233.33% | Stifel | Benjamin Burnett | $4.8 → $2.3 | Maintains | Hold | Get Alert |
| 11/10/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | -27.54% | Goldman Sachs | Tommie Reerink | $3 → $0.5 | Maintains | Sell | Get Alert |
| 11/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | — | Evercore ISI Group | Michael DiFiore | — | Downgrade | Outperform → In-Line | Get Alert |
| 11/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | — | HC Wainwright & Co. | Robert Burns | — | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 44.93% | Mizuho | Salim Syed | $31 → $1 | Downgrade | Buy → Neutral | Get Alert |
| 09/26/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3957.97% | HC Wainwright & Co. | — | → $28 | Reiterates | Buy → Buy | Get Alert |
| 08/21/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 102.9% | Citigroup | Yigal Nochomovitz | $2 → $1.4 | Maintains | Sell | Get Alert |
| 08/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3523.19% | EF Hutton | Anthony Butler | → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3957.97% | HC Wainwright & Co. | Robert Burns | $27 → $28 | Maintains | Buy | Get Alert |
| 05/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 2798.55% | Canaccord Genuity | John Newman | $50 → $20 | Maintains | Buy | Get Alert |
| 02/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3523.19% | EF Hutton | Anthony Butler | → $25 | Reiterates | → Buy | Get Alert |
| 02/09/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3813.04% | HC Wainwright & Co. | Robert Burns | $29 → $27 | Maintains | Buy | Get Alert |
| 02/07/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 4392.75% | Mizuho | Salim Syed | → $31 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 3523.19% | EF Hutton | Tony Butler | → $25 | Initiates | → Buy | Get Alert |
| 08/16/2022 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 4392.75% | Mizuho | Salim Syed | $39 → $31 | Maintains | Buy | Get Alert |
| 08/09/2022 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 334.78% | Goldman Sachs | Tommie Reerink | $4 → $3 | Maintains | Sell | Get Alert |
| 07/20/2022 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 334.78% | Citigroup | Yigal Nochomovitz | → $3 | Downgrade | Neutral → Sell | Get Alert |
| 07/13/2022 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 1349.28% | JP Morgan | Anupam Rama | → $10 | Downgrade | Overweight → Neutral | Get Alert |
| 07/13/2022 | ATRA | Buy Now | Atara Biotherapeutics | $0.69 | 624.64% | Stifel | Benjamin Burnett | $16 → $5 | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Atara Biotherapeutics (ATRA)?
The latest price target for Atara Biotherapeutics (NASDAQ: ATRA) was reported by Stifel on April 1, 2024. The analyst firm set a price target for $2.30 expecting ATRA to rise to within 12 months (a possible 233.33% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Atara Biotherapeutics (ATRA)?
The latest analyst rating for Atara Biotherapeutics (NASDAQ: ATRA) was provided by Stifel, and Atara Biotherapeutics maintained their hold rating.
When was the last upgrade for Atara Biotherapeutics (ATRA)?
The last upgrade for Atara Biotherapeutics Inc happened on May 13, 2021 when JP Morgan raised their price target to $29. JP Morgan previously had a neutral for Atara Biotherapeutics Inc.
When was the last downgrade for Atara Biotherapeutics (ATRA)?
The last downgrade for Atara Biotherapeutics Inc happened on November 9, 2023 when Evercore ISI Group changed their price target from N/A to N/A for Atara Biotherapeutics Inc.
When is the next analyst rating going to be posted or updated for Atara Biotherapeutics (ATRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Atara Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Atara Biotherapeutics was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.
Is the Analyst Rating Atara Biotherapeutics (ATRA) correct?
While ratings are subjective and will change, the latest Atara Biotherapeutics (ATRA) rating was a maintained with a price target of $4.80 to $2.30. The current price Atara Biotherapeutics (ATRA) is trading at is $0.69, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.